A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 30 Oct 2024
Price :
$35 *
At a glance
- Drugs Calaspargase pegol (Primary) ; Cobimetinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms Casper
- 28 Oct 2024 Planned primary completion date changed from 16 Dec 2024 to 16 Dec 2025.
- 28 Mar 2023 Planned number of patients changed from 24 to 15.
- 21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium.